General Foods Corporation v. Studiengesellschaft Kohle Mbh

972 F.2d 1272, 1992 WL 191182
CourtCourt of Appeals for the Federal Circuit
DecidedOctober 2, 1992
Docket91-1418
StatusPublished
Cited by60 cases

This text of 972 F.2d 1272 (General Foods Corporation v. Studiengesellschaft Kohle Mbh) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
General Foods Corporation v. Studiengesellschaft Kohle Mbh, 972 F.2d 1272, 1992 WL 191182 (Fed. Cir. 1992).

Opinion

RICH, Circuit Judge.

Studiengesellschaft Kohle mbH (SGK), as trustee for real-party-in-interest Max Planck Institute for Coal Research, appeals from the June 12, 1991 judgment of the United States District Court for the Southern District of New York, Civil Action No. 88-8343, declaring invalid claims 1 and 4 of SGK’s U.S. Patent No. 4,260,639 (’639 patent), titled “Process for the Decaffeination of Coffee,” on the sole ground of “double patenting,” in view of SGK’s earlier-issued U.S. Patent No. 3,806,619 ('619 patent), titled “Process for Recovering Caffeine.” Because there is no double patenting, we reverse.

BACKGROUND

This declaratory judgment suit is between a licensor and licensee over patents relating to decaffeinated coffee. Plaintiff, General Foods Corporation (GF), owns Maxwell House Coffee Company which manufactures decaffeinated coffee at its AMCO plant in Houston, Texas, for sale under brands such as Sanka, Maxim, Brim, Yuban, and Maxwell House. GF also owns Kaffee HAG, a processor and research company in Bremen, Germany, which is said to have been the first producer of decaffeinated coffee.

SGK developed in Europe inventions relating to decaffeination and owned five United States patents involved in this lawsuit. Learning about SGK’s developments, GF entered into an exclusive license agreement with SGK effective February 1, 1978, which has now become a nonexclusive license, on which it paid royalties to SGK through 1990, since then paying further royalties under protest. The license agreement provided for advance payments total-ling $1,800,000 during the first year. Royalties were to range from 1.76% of net decaffeinated coffee sales up to 40,000,000 *1274 pounds down to 1.25% of net sales over 120,000,000 pounds.

GF brought this suit for a declaration of non-infringement, invalidity, and unen-forceability as to all five patents. However, the District Court found that although all five SGK patents were licensed, SGK now asserts that only claims 1 and 4 of the ’639 patent would be infringed by GF’s operation at the AMCO plant and that the other four patents are no longer in suit. Although GF asserted numerous defenses against claims 1 and 4, including invalidity for “obviousness-type double patenting,” non-infringement, obviousness under 35 U.S.C. § 103, non-enablement under 35 U.S.C.. § 112, and unenforceability due to inequitable conduct before the Patent and Trademark Office (PTO), the District Court issued an Order of Trial on April 5, 1991, on GF’s motion, to “bifurcate the issue of double patenting.” The order further stated, “If the decision does not dispose of the action, trial will then immediately continue on the remaining issues.”

The District Court held a separate trial on the single issue of double patenting. A judgment was entered holding claims 1 and 4 of the ’639 patent invalid, thus terminating GF’s declaratory judgment suit seeking invalidity of the only patent it was alleged to be infringing and putting an end to its obligation to pay SGK royalties under its contract. 765 F.Supp. 121.

This appeal followed and, as above stated, there is only one issue for us to decide — is there double patenting. We shall first discuss the facts regarding the two patents involved and then the law of double patenting as it applies to those facts.

Patent Claims

Preliminarily, in order to better focus on the crucial aspects of the patents under discussion, we make the following elementary observations about patent claims. The patent document which grants the pat-entee a right to exclude' others and hence bestows on the owner the power to license, consists of two primary parts: (1) a written description of the invention, which may and here does include drawings, called the “specification,” enabling those skilled in the art to practice the invention, and (2) claims which define or delimit the scope of the legal protection which the government grant gives the patent owner, the patent “monopoly.” As stated by Judge Lane, who served on both of our predecessor courts, in In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA1970), “A claim is a group of words defining only the boundary of the patent monopoly.” (Emphasis ours.) The Supreme Court has likened patent claims to the description of real property in a deed “which sets the bounds to the grant which it contains. It is to the claims of every patent, therefore, that we must turn when we are seeking to determine what the invention is, the exclusive use of which is given to the inventor by the grant provided for in the statute, — ‘He can claim nothing beyond them.’ ” Motion Picture Patents Co. v. Universal Film Mfg. Co., 243 U.S. 502, 510, 37 S.Ct. 416, 418, 61 L.Ed. 871 (1917) (emphasis ours).

That being the essential nature of patent claims, it follows that each claim is an entity which must be considered as a whole. It cannot be said — though it often is, incorrectly, by the uninitiated — that a part of a claim is “claimed” subject matter. For example, a claim to a process comprising the step A followed by step B followed by step C defines, as a matter of law, only the A-B-C process and one cannot properly speak of any single step as being “claimed”, for it is not; all that is claimed is the process consisting of the combination of all three steps. Such a claim, therefore, creates no patent right or monopoly in step A, no right to prevent others from using step A apart from the combination of steps A-B-C. Step A is not “patented.”

Another way of stating the legal truism is that patent claims, being definitions which must be read as a whole, do not “claim” or cover or protect all that their words may disclose. Even though the claim to the A-B-C combination of steps contains a detailed description of step A, that does not give the patentee any patent *1275 right in step A and it is legally incorrect to say that step A is “patented.”

These legal rules about construing claims are repeated here because the law of double patenting is concerned only with what patents claim. “Double patenting,” therefore, involves an inquiry into what, if anything, has been claimed twice.

The Patent in Suit and its Claimed Invention

Coffee beans contain a small percentage of caffeine which must be removed to produce decaffeinated coffee. The inventor, Kurt Zosel, working in Germany for SGK, discovered that moist (i.e., containing water) “supercritical” carbon dioxide, that is, carbon dioxide above its critical temperature and critical pressure, was an excellent solvent for taking the caffeine out of coffee beans. That was the basic invention. The parties and the trial court have referred to the patent on this invention as “the decaffeination patent.”

A U.S. application for patent on this invention was filed January 28, 1971, serial No. 110,428.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Purdue Pharma L.P. v. Collegium Pharm., Inc.
335 F. Supp. 3d 149 (District of Columbia, 2018)
Ucb, Inc. v. Accord Healthcare, Inc.
890 F.3d 1313 (Federal Circuit, 2018)
Gilead Sciences, Inc. v. Natco Pharma Limited
753 F.3d 1208 (Federal Circuit, 2014)
Eli Lilly and Co. v. Teva Parenteral Medicines, Inc.
689 F.3d 1368 (Federal Circuit, 2012)
Stern v. Sequal Technologies, Inc.
840 F. Supp. 2d 1260 (W.D. Washington, 2012)
Fujitsu Ltd. v. Belkin International, Inc.
782 F. Supp. 2d 868 (N.D. California, 2011)
Sun Pharmaceutical Industries, Ltd. v. Eli Lilly & Co.
625 F.3d 719 (Federal Circuit, 2010)
In Re Basell Poliolefine Italia S.P.A.
547 F.3d 1371 (Federal Circuit, 2008)
Amgen, Inc. v. F. Hoffmann-La Roche Ltd.
581 F. Supp. 2d 160 (D. Massachusetts, 2008)
Fisher-Barton Blades, Inc. v. Blount, Inc.
584 F. Supp. 2d 1126 (E.D. Wisconsin, 2008)
BMC Resources, Inc. v. Paymentech, L.P.
498 F.3d 1373 (Federal Circuit, 2007)
Takeda Pharmaceutical Co., Ltd. v. Dudas
511 F. Supp. 2d 81 (District of Columbia, 2007)
In Re Metoprolol Succinate Patent Litigation
494 F.3d 1011 (Federal Circuit, 2007)
AstraZeneca AB v. KV Pharmaceutical Co.
494 F.3d 1011 (Federal Circuit, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
972 F.2d 1272, 1992 WL 191182, Counsel Stack Legal Research, https://law.counselstack.com/opinion/general-foods-corporation-v-studiengesellschaft-kohle-mbh-cafc-1992.